for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Limited

PFIZ.NS

Latest Trade

5,318.65INR

Change

91.40(+1.75%)

Volume

522,316

Today's Range

5,275.00

 - 

5,436.60

52 Week Range

3,461.00

 - 

5,900.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
5,227.25
Open
5,350.00
Volume
522,316
3M AVG Volume
2.06
Today's High
5,436.60
Today's Low
5,275.00
52 Week High
5,900.00
52 Week Low
3,461.00
Shares Out (MIL)
45.75
Market Cap (MIL)
233,663.40
Forward P/E
45.44
Dividend (Yield %)
0.20

Latest Developments

More

Canada tentatively expects to get Pfizer vaccine in early 2021, perhaps after the U.S. and Britain - government source

India's Pfizer June Qtr Net Profit Rises

Pfizer Ltd - Declared A Special Dividend Of 320 Rupees Per Equity Share

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Limited

Pfizer Limited is an India-based pharmaceutical company. The Company has a portfolio of approximately 140 products across over 15 therapeutic areas. The Company is engaged in manufacturing, marketing, trading and exporting pharmaceutical products. The Company offers a range of products for Anti-Allergic, Anti-Diabetic, Antihistamine, Anti-Infectives, Cardiovascular, Dermatology, Erectile Dysfunction, gastrointestinal (GI), Multivitamins, Pain/Inflammation+GI, Respiratory, Urology and Vitamin/Minerals, among others. Its products include LC-OD Plus, Bidiab, Voglibose, Histizer, Isokin, Jetex Suspension, Nebasulf Ointment, Trulimax, Combantrin A, Newsta, Selsun, Agarol, Oxileptin, Ponstan, Daxid, Tricorex, Citrosoda and Cognisules, among others. The Company has its own manufacturing facility at Thane and Goa. The Company has various independent contract/third party manufacturers based across the country. The Company sells its products through independent distributors primarily in India.

Industry

Major Drugs

Contact Info

Pfizer Centre, 5, Patel Estate

Off S.V. Road, Jogeshwari (W)

400051

India

+91.22.66932000

http://www.pfizerindia.com/

Executive Leadership

Rajendra A. Shah

Independent Non-Executive Chairman of the Board

Milind Patil

Executive Director - Finance, Director

Prajeet Nair

Compliance Officer, Company Secretary

S. Sridhar

Managing Director, Whole Time Director

Aijaz Tobaccowalla

Executive Director

Key Stats

2.14 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2018

19.7K

2019

20.8K

2020

21.5K

2021(E)

22.5K
EPS (INR)

2018

78.700

2019

93.780

2020

111.280

2021(E)

112.462
Price To Earnings (TTM)
46.93
Price To Sales (TTM)
10.87
Price To Book (MRQ)
10.91
Price To Cash Flow (TTM)
38.57
Total Debt To Equity (MRQ)
4.33
LT Debt To Equity (MRQ)
4.22
Return on Investment (TTM)
18.05
Return on Equity (TTM)
13.86

Latest News

Latest News

BRIEF-India's Pfizer March Quarter Net Profit Falls

* MARCH QUARTER NET PROFIT 1.03 BILLION RUPEES VERSUS 1.09 BILLION RUPEES YEAR AGO

BRIEF-Pfizer Ltd - Declared A Special Dividend Of 320 Rupees Per Equity Share

* PFIZER LTD - DECLARED A SPECIAL DIVIDEND OF 320 RUPEES PER EQUITY SHARE Source text for Eikon: Further company coverage:

BRIEF-India's Pfizer Ltd Dec Quarter Profit Rises

* DEC QUARTER NET PROFIT 1.39 BILLION RUPEES VERSUS 1.32 BILLION RUPEES YEAR AGO

REFILE-BRIEF-India's Pfizer Ltd Says News On Stopping Ops In Chennai, Aurangabad Units Unrelated To Co

* CLARIFIES ON NEWS ARTICLE ABOUT PFIZER TO STOP MANUFACTURING OPERATIONS IN CHENNAI, AURANGABAD UNITS

BRIEF-India's Pfizer March Qtr Profit Rises

* MARCH QUARTER NET PROFIT 1.05 BILLION RUPEES VERSUS PROFIT OF 680.4 MILLION RUPEES YEAR AGO

BRIEF-Pfizer Ltd Says Pfizer Inc Has Not Yet Made Decision w.r.t Strategic Alternatives For Global Consumer Healthcare Business​

* PFIZER INC. TOLD CO'S BOARD THAT NO DECISION HAS YET BEEN MADE WITH RESPECT TO ANY STRATEGIC ALTERNATIVES FOR GLOBAL CONSUMER HEALTHCARE BUSINESS

BRIEF-Pfizer Says Ravi Prakash Bhagavathula Resigned As CFO

* SAYS RAVI PRAKASH BHAGAVATHULA RESIGNED AS CFO Source text - http://bit.ly/2CxVrV6 Further company coverage:

BRIEF-India's Pfizer Dec-Qtr Profit Rises

* DEC QUARTER NET PROFIT 872.4 MILLION RUPEES VERSUS PROFIT OF 623.7 MILLION RUPEES YEAR AGO

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up